Hypertension is a multifactorial and multisystem disease in which elevated blood pressure is only one sign of multiple underlying physiological abnormalities. It affects approximately 26% of the population worldwide. Hypertension is one of the leading cause of death as a "silent killer". Several classes of antihypertensive agents have been in clinical use, but CCBs exert most potent antihypertensive action and are widely used as a first line antihypertensive drug in elderly with very few contraindication.Four generations of dihydropyridines CCBs are now available.The fourth-generation highly lipophilic dihydropyridines, lercanidipine, cilnidipine and lacidipine are now available which provide a real degree of therapeutic comfort in terms of stable activity, a reduction in adverse effects and a broad therapeutic spectrum. Cilnidipine is a recently developed CCB, and possesses both L-and N-type calcium channel blocking activity.Cilnidipine causing less reflex tachycardia, less pedal edema, better control of proteinuria, suppressing podocyte damage, increasing insulin sensitivity.This article reviews the current understanding of the pharmacological profile and clinical utility of cilnidipine as a unique antihypertensive drug.
potent antihypertensive action and are widely used as a first lineantihypertensive drug in elderly with very few contraindication. [5] [6] [7] [8] [9] These reliable CCBs not only use in hypertension but also in angina and peripheral vascular disease. [10] [11] The aim of the review is to assess the potential advantages and disadvantages of newer CCBs with a focus of its benefits in varied cardio vascular diseases.
Calcium Channel Blocker (CCB)
Calcium channel blockers (CCBs), comprising two subclasses-dihydropyridines and nondihydropyridines. Calcium channel blockers (CCBs) share a common mechanism of action. However, the manner in which they exert their pharmacological effects is different between subclasses. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) agents, whereas the latter have more marked negative inotropic effects. Both subclasses have a similar capacity to lower BP; however, non-DHPs appear to offer potential advantages in the management of patients with chronic kidney disease and diabetic nephropathy. Since its invention in 1960s, Dihydropyridines have undergone several changes to optimize their efficacy and safety for the management of cardiovascular disease. 4, 12, 13, 14 Four generations of dihydropyridines are now available. The first-generation nicardipine and nifedipine are potent and low cost antihypertensive drug. However, because of their short duration and rapid onset of vasodilator action, these drugs were more likely to be associated with adverse effects like; headache, blood pressure fluctuation. The new second generation slow-release and short-acting preparations like benidipine, and efonidipine allowed better control of blood pressure and a reduction in some adverse effects. The thirdgeneration dihydropyridines, amlodipine and azelnidipine exhibit more stable pharmacokinetics, are less cardio-selective and, consequently, well tolerated in patients with heart failure. The fourthgeneration highly lipophilic dihydropyridines, lercanidipine, cilnidipine and lacidipine are now available which provide a real degree of therapeutic comfort in terms of stable activity, a reduction in adverse effects and a broad therapeutic spectrum, especially in myocardial ischemia and potentially in congestive heart failure. 12, 15 
CCBs-Mechanism of Action
The voltage-gated calcium channel consists of 4 subunits, α1, α2-δ, β and γ. An α1 subunit is the dominant component of the calcium channels and constitutes pore structure for ion conduction. Ten different α1 subunits have been reported and each of them has specific distribution and ion conductance of its channels. These distinct subunits characterize the channel properties of L-, N-, T-, P-, Q-and Rtype calcium channels. Of these channels, L-type calcium channels are the main targets of the CCB. 16, 17 Traditionally, CCBs exert dilator action on vascular smooth muscle cells by inhibiting calcium entry through L-type calcium channels. Recently, novel types of CCBs have been developed that blocking activity on N-(cilnidipine) and/or T-(mibefradil and efonidipine) type calcium channels as well as Ltype channels, and these properties produce additional benefits associated with reductions in cardiovascular events and renal injury. For example, the blockade of N-type or T-type calcium channels in cardiac pacemaker cells may suppress heart rates, which could therefore reduce cardiac events and improve survival. 18, 19 Cilnidipine is a recently developed CCB, and possesses both L-and N-type calcium channel blocking activity. 20 Since N-type calcium is distributed along the nerve and in the brain, cilnidipine is anticipated to exert specific action on nerve activity, such as inhibition of the sympathetic neuro transmitter release. N-type calcium channels regulate sympathetic nerve activity, and aberrant sympathetic nerve stimulation is a major cause of hypertension. 18,21 Because sympathetic nerve stimulation causes release of norepinephrine which causes vasoconstriction, increase cardiac contraction, increase heart rate, decrease of renal blood flow, renin secretion. All these actions increases systemic blood pressure (Fig-1 ). 15 Cilnidipine inhibits N-type Ca2þ channels more potently than other Ca2þ channel blockers and several in vitro studies conducted by Nap A et al. (2004) , have demonstrated that cilnidipine attenuates norepinephrine release from sympathetic nerve endings. 22,23 Furthermore, such effects have been observed in in vivo experiments using anesthetized rats 24 and dogs. 25 This article reviews the current understanding of the pharmacological profile and clinical utility of cilnidipine as a unique antihypertensive drug. 
Role of 4 th Generation CCBs in Various Clinical Settings

Antihypertensive Effects
The antihypertensive effect of cilnidipine has been demonstrated in various studies conducted among hypertensive patients. Once-daily administration of cilnidipine (5-20 mg) for 1-3 weeks decreased the 24-hour average BP significantly from 149±4/88±2 mmHg to 141±3/82±2 mmHg without any change in the pulse rate. Cilnidipine is thus a useful antihypertensive drug that may not cause an excessive decrease in blood pressure or a reflex tachycardia. 26 Sympatholytic profiles of cilnidipine observed in both in vitro and in vivo, are also observed in clinical practice. 24 In clinical studies, conducted by Nagahama S et al. (2007) and Iimura O et al (1993) the antihypertensive effect of cilnidipine has been demonstrated in hypertensive patients, 27 and also in patients with severe hypertension. 28 In a study conducted in 2920 hypertensive patients, treatment with cilnidipine and angiotensin receptor blocker showed significant reductions in heart rate, particularly in those with a higher baseline heart rate, whereas there were few adverse reactions associated with central nervous functions. 27 In another study conducted by Minami J et al. (2000) in patients with mild to moderate essential hypertension, Cilnidipine significantly decreased the 24 h blood pressure by 6.5±1.7 mm Hg systolic (P<0.01) and 5.0±1.1 mmHg diastolic (P<0.01), also cilnidipine did not significantly change the heart rate. 29 It was concluded by Minami J et al., that Cilnidipine is effective as a once daily antihypertensive agent and causes little influence on heart rate. 29 Hoshide et al (2005) 30 demonstrated that the reductions in heart rate were significantly greater in the cilnidipine group than the amlodipine group in a 24-h ambulatory blood pressure monitoring study with hypertensive patients. 30 Kai T et al. (2009) conducted a study to examine the effects of cilnidipine, on blood pressure, pulse rate, and autonomic functions in patients with mild-tomoderate hypertension. The systolic or diastolic blood pressure decreased significantly from 151±15 mmHg to 129±14 mmHg or 84±11 mmHg to 71±9 mmHg, respectively. No significant changes in pulse rate was reported. 31 Cilnidipine significantly decreased morning hypertension. In ACHIEVE-ONE trial, the effects of cilnidipine on morning hypertension were examined in 2319 patients treated with cilnidipine for 12 weeks. Cilnidipine reduced both morning systolic blood pressure (SBP) and pulse rate (PR) more markedly in patients with higher baseline morning SBP and PR. Also a 12-week treatment with cilnidipine significantly, restored abnormal nocturnal dipping in hypertensive patients. 32, 33, 34 Cilnidipine has been clinically demonstrated to be effective for morning hypertension and white-coat hypertension, which is closely associated with sympathetic nerve over activation. 35 Cilnidipine, also a good option for combination therapy. Treatment with cilnidipine and ARB showed a significant reduction in SBP (p<0.0001) and DBP (p<0.0001). 27 
Other Effect on Heart
Six months treatment with cilnidipine improved LV diastolic function in patients with hypertensive heart disease by suppressing cardiac sympathetic over activity. 36 The CANDLE trialand other clinical studies have demonstrated that treatment with cilnidipine 5-10 mg/day for 8 weeks can improve left-ventricular systolic function independently of blood pressure changes. 37 Cilnidipine causes a greater decrease in Left Ventricular Mass (LVM) in essential hypertension than quinapril. 38 The cardioprotective action of cilnidipine has been analyzed in a rabbit model of myocardial infarction, in which cilnidipine decreased the myocardial interstitial norepinephrine levels during ischemia and reperfusion periods, leading to reduction of the myocardial infarct size and incidence of ventricular premature beats. 39 Furthermore, in vivo experimental data have suggested that cilnidipine shows antianginal effects in the experimental model of vasopressin-induced angina and improvement of the ventricular repolarization abnormality in the canine model of long QT syndrome. 40, 41 
Effect on Kidney
Hypertension is one of the most important risk factors for the progression of renal disease. Moreover, chronic renal dysfunction, proteinuria or albuminuria are independent risk factors for cerebrovascular and cardiovascular diseases. The CARTER clinical studies have shown that cilnidipine, has better renal protection compared with other dihydropyridine CCBs. 42 CARTER study which is a multi-center, open-labeled, and randomized trial compared the antiproteinuric effect of cilnidipine with that of amlodipine in 339 hypertensive patients with kidney disease. This study suggests that cilnidipine is superior to amlodipine in preventing the progression of proteinuria in hypertensive patients when coupled with a renin-angiotensin system inhibitor. 42 Podocytes act as a permeability barrier in glomeruli restricting the passage of large molecules like albumin. Albuminuria is the primary indicator of a defective glomerular filtration barrier. Various glomerular diseases that induce proteinuria also shown structural damage to podocytes. 43 A decrease in the number of podocytes has been reported in diabetic nephropathy. 44 Cilnidipine provides protection of glomeruli by both afferent and efferent arteriolar vasodilation in glomeruli (Figure 2 ). This causes reduction of glomerular pressure further result in significant reduction of proteinuria. 43 In an open-label, randomized controlled trial the effects of cilnidipine in 60 patients with CKD were investigated. After 12 months, proteinuria and heart rate were significantly decreased in the cilnidipine treated patients, but proteinuria increased and heart rate remained unchanged in patients treated with CCB acting on L-type channel (L-CCB). 45 TACTICAL trial evaluatedantioxidative and antiproteinuriceffects of cilnidipine as comparedto amlodipine. This study reported significant decrease in the urinary albumin/creatinine ratio after 6 month treatment with cilnidipine as compared to amlodipine treatment (p<0.005). 46 In clinical studies, Rose and Ikebukoro 47 demonstrated that cilnidipine significantly decreased urinary albumin excretion without affecting serum creatinine concentration in hypertensive patients, which is comparable to the angiotensin converting enzyme inhibitor benazepril. 47 Recently, prevalence of cardiovascular disease and cardiovascular mortality have been suggested to be closely associated with renal function; namely, cardioerenal connection. 46 Thus, the renal protective effects of cilnidipine may secondarily contribute to cardioprotection. 48 
Effect on Insulin Sensitivity
Cilnidipine improve insulin sensitivity, possibly due to its vasodilatory action without stimulating sympathetic nervous activity. The benefit effects of cilnidipine on glucose metabolism is an important site for the treatment of hypertensive patients with insulin resistance and/or diabetes mellitus. 49 Hypertensive obese patients treated with 10 mg of cilnidipine showed improved in insulin resistance. 50 
Effect on CCBs induced ankle edema
Ranjan Shetty, et al. (2013) have conducted a study in patients of essential hypertension with amlodipine induced ankle edema. They had found that cilnidipine resulted in complete resolution of amlodipine induced edema in all the cases without significant worsening of hypertension or tachycardia. Cilnidipine is an acceptable alternative antihypertensive for patients with amlodipine-induced edema. 51
Drawback of Cilnidipine
Cilnidipine is contraindicated in patients with severe aortic stenosis, cardiogenic shock, recent history of unstable angina or MI, heart failure and hypotension. The recommended adult oral dosage of Cilnidipine is 5-10 mg once daily. The dosage can be increased up to 20 mg, if needed. But in our clinical observation, 5 mg of Cilnidipine in comparison to 5mg of Amlodipine is very weak as a single antihypertensive drug. Sometimes it is require to start with 10 mg of Cilnidipine for adequate antihypertensive effect. But we did not get enough clinical study evidence regarding this issue.
Conclusion
Hypertension is one of the most common noncommunicable disease seen in primary care sating and a major public health problem. It is one of the most significantly under-diagnosed and under-treated medical conditions all over the world. If left untreated can led to various complications. For more than 50 years, CCB is one of the most reliable antihypertensive drug. Several classes of CCBs are in clinical use for the treatment of hypertension because of potent vasodepressor action. Among CCB, Cilnidipine is a promising 4th generation Ca 2+ channel blocker with its unique action onsympathetic N-type Ca 2+ channels inhabit norepinephrine release and leads to vasodilatation, decrease in heart rate and increase in renal blood flow. Cilnidipine causing less reflex tachycardia, less pedal edema, better control of proteinuria, suppressing podocyte damage, increasing insulin sensitivity. Therefore, Cilnidipine as CCB can be a good choice in hypertensive patients with diabetes, chronic kidney disease and in patients developing pedal edema with other CCB. 
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